16.43
Precedente Chiudi:
$17.82
Aprire:
$17.2
Volume 24 ore:
119.54K
Relative Volume:
0.96
Capitalizzazione di mercato:
$179.97M
Reddito:
$56.54M
Utile/perdita netta:
$-30.70M
Rapporto P/E:
-42.13
EPS:
-0.39
Flusso di cassa netto:
$-31.05M
1 W Prestazione:
-26.62%
1M Prestazione:
-29.06%
6M Prestazione:
+50.73%
1 anno Prestazione:
-23.94%
Cidara Therapeutics Inc Stock (CDTX) Company Profile
Nome
Cidara Therapeutics Inc
Settore
Industria
Telefono
858-752-6170
Indirizzo
6310 NANCY RIDGE DRIVE, SAN DIEGO, CA
Confronta CDTX con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
CDTX
Cidara Therapeutics Inc
|
16.43 | 179.97M | 56.54M | -30.70M | -31.05M | -0.39 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Cidara Therapeutics Inc Stock (CDTX) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-03-12 | Iniziato | Citizens JMP | Mkt Outperform |
2025-01-27 | Ripresa | Cantor Fitzgerald | Overweight |
2024-12-13 | Iniziato | RBC Capital Mkts | Outperform |
2024-11-08 | Iniziato | Guggenheim | Buy |
2024-08-14 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
2021-12-03 | Ripresa | H.C. Wainwright | Buy |
2021-09-22 | Aggiornamento | WBB Securities | Buy → Strong Buy |
2021-03-04 | Iniziato | Aegis Capital | Buy |
2019-09-04 | Aggiornamento | Wedbush | Neutral → Outperform |
2018-07-26 | Iniziato | Citigroup | Buy |
2017-04-21 | Iniziato | Raymond James | Strong Buy |
2017-04-17 | Reiterato | H.C. Wainwright | Buy |
2017-04-12 | Iniziato | Ladenburg Thalmann | Buy |
2017-04-11 | Ripresa | Wedbush | Outperform |
2017-02-22 | Reiterato | H.C. Wainwright | Buy |
2017-02-22 | Aggiornamento | WBB Securities | Sell → Hold |
2016-12-21 | Ripresa | Leerink Partners | Outperform |
2016-12-19 | Iniziato | H.C. Wainwright | Buy |
2016-09-23 | Downgrade | WBB Securities | Hold → Sell |
2015-10-09 | Aggiornamento | WBB Securities | Sell → Hold |
2015-05-11 | Iniziato | Jefferies | Buy |
2015-05-11 | Iniziato | Leerink Partners | Outperform |
2015-05-11 | Iniziato | Needham | Buy |
2015-05-11 | Iniziato | Wedbush | Outperform |
2015-04-23 | Iniziato | WBB Securities | Sell |
Mostra tutto
Cidara Therapeutics Inc Borsa (CDTX) Ultime notizie
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Sees Significant Increase in Short Interest - Defense World
Cidara Therapeutics (NASDAQ:CDTX) Shares Pass Above 50 Day Moving Average – Time to Sell? - Defense World
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - GlobeNewswire
New Executive Joins Cidara Therapeutics with $580K+ Stock Compensation Package - Stock Titan
Cidara Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
Cidara Therapeutics Unveils Latest Innovations at Elite Needham Healthcare Conference - Stock Titan
(CDTX) Investment Analysis - news.stocktradersdaily.com
Elicio Therapeutics Hires CFO From Cidara Therapeutics - MarketWatch
Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer - GlobeNewswire
Wall Street Analysts Predict a 64.5% Upside in Cidara Therapeutics (CDTX): Here's What You Should Know - MSN
Cidara Therapeutics to Participate in World Health - GlobeNewswire
Cidara Therapeutics to present on CD388 at ICAR 2025 - Yahoo Finance
Cidara's Breakthrough H5N1 Flu Drug Takes Center Stage at WHO Emergency Preparedness Meeting - StockTitan
Short Interest in Cidara Therapeutics, Inc. (NASDAQ:CDTX) Increases By 30.7% - Defense World
Cidara Therapeutics Announces Two Presentations on CD388 in - GlobeNewswire
Major Milestone: Cidara's Novel Flu Prevention Drug Completes Massive 5,000-Patient Trial - StockTitan
Cidara Therapeutics Announces Publication of CD388 Preclinical Data in Nature Microbiology - GlobeNewswire
Revolutionary Universal Flu Drug Shows Promise Against All Strains, Including Bird Flu - StockTitan
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives $39.14 Average Target Price from Analysts - Defense World
(CDTX) Long Term Investment Analysis - Stock Traders Daily
Citizens Jmp Begins Coverage on Cidara Therapeutics (NASDAQ:CDTX) - Defense World
Cidara therapeutics COO Shane Ward sells shares worth $36,542 By Investing.com - Investing.com Australia
Cidara therapeutics chief scientific officer sells shares worth $38,939 By Investing.com - Investing.com Australia
Cidara therapeutics COO Shane Ward sells shares worth $36,542 - Investing.com India
Cidara therapeutics chief scientific officer sells shares worth $38,939 - Investing.com India
Cidara Therapeutics Executives Sell Shares to Cover Tax Obligations - TradingView
HC Wainwright Issues Negative Estimate for CDTX Earnings - Defense World
Citizens Capital Markets Initiates Coverage of Cidara Therapeutics (CDTX) with Market Outperform Recommendation - Nasdaq
Cidara stock gains on Citizens' bullish view (CDTX:NASDAQ) - Seeking Alpha
Cidara Therapeutics initiated with an Outperform at Citizens JMP - TipRanks
Cidara stock gains on JMP analyst’s upbeat outlook By Investing.com - Investing.com Canada
FY2029 Earnings Forecast for CDTX Issued By HC Wainwright - Defense World
Buy Rating for Cidara Therapeutics: Promising Potential of CD388 in Influenza Prevention - TipRanks
HC Wainwright Issues Positive Forecast for Cidara Therapeutics (NASDAQ:CDTX) Stock Price - Defense World
Cidara stock price target raised to $35 at H.C. Wainwright By Investing.com - Investing.com Canada
Cidara Therapeutics price target raised to $35 from $24 at H.C. Wainwright - TipRanks
Ed Arce’s Buy Rating for Cidara Therapeutics Driven by Accelerated CD388 Program and Promising Phase 2b NAVIGATE Study Developments - TipRanks
Head-To-Head Analysis: Cidara Therapeutics (NASDAQ:CDTX) vs. Neumora Therapeutics (NASDAQ:NMRA) - Defense World
Needham & Company LLC Reaffirms “Buy” Rating for Cidara Therapeutics (NASDAQ:CDTX) - Defense World
Cidara Therapeutics Faces Financial Risks Amid Delayed Annual Report Filing - TipRanks
Cidara Therapeutics Advances with Strong Financial Backing - TipRanks
Contrasting Cidara Therapeutics (NASDAQ:CDTX) and Scinai Immunotherapeutics (NASDAQ:SCNI) - Defense World
Cidara Therapeutics: Q4 Earnings Snapshot - Barchart
Cidara Therapeutics reports wider Q4 loss, shares dip - Investing.com
Cidara Therapeutics reports wider Q4 loss, shares dip By Investing.com - Investing.com South Africa
Cidara Therapeutics Inc Azioni (CDTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cidara Therapeutics Inc Azioni (CDTX) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Tari Leslie | CHIEF SCIENTIFIC OFFICER |
Mar 11 '25 |
Sale |
21.96 |
1,773 |
38,940 |
16,215 |
Sandison Taylor | Chief Medical Officer |
Sep 11 '24 |
Sale |
11.64 |
924 |
10,752 |
23,067 |
Tari Leslie | CHIEF SCIENTIFIC OFFICER |
Sep 11 '24 |
Sale |
11.64 |
909 |
10,580 |
17,788 |
Stein Jeffrey | President & CEO |
Jun 07 '24 |
Buy |
13.21 |
8,000 |
105,680 |
24,580 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):